Mainz Biomed B.V. (NASDAQ: MYNZ) – Fundamental Analysis

Mainz Biomed BV (NASDAQ: MYNZ) is engaged in developing molecular genetic diagnostic solutions for life-threatening conditions. It’s main product Coloalert is a kit that includes a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results.

Key Reasons To Get This Potentially Undervalued Idea On Your Radar ASAP

• The Company’s Flagship Product (ColoAlert) Could Become An Inexpensive Alternative In A $3.7 Billion Market
• The Company Recently Acquired Exclusive Rights To Novel mRNA Biomarkers
• If And When The Company Receives FDA Premarket Approval For Its ColoAlert Flagship Product, It Could Become A Game-Changing Milestone
• Another Key Pipeline Product Could Detect What May Become The World’s Second Most Deadly Cancer
• Company insiders are still sitting on over 23% of available shares as of June 10, 2022. Not to mention, Mainz Biomed only has 11.9 million shares available in its float.
• Mainz Biomed just announced the company has successfully completed the conformity assessment of its internal processes to In Vitro Diagnostic Devices Regulation (IVDR) compliance which becomes mandatory from May 26, 2022.

That's how Mainz BioMed could take full advantage of a $3.7 BILLION market opportunity with its blockbuster early detection test for Colorectal Cancer. This is the perfect add to watch-list stock and do your due diligence.

This business has huge potential, so check out this article for a further analysis on the company.

https://markettradersreport.com/molecular-genetics/?utm_source=dmreddit&utm_medium=influencer&utm_campaign=mynzz_us

…

Disclaimer: “This User has been paid $200USD by a third party to provide coverage on 06/20-24/2022 for Mainz Biomed B.V. (MYNZ).”